{
  "id": 900396,
  "title": "Tech stock hits 52-week high at 72.39 USD",
  "url": "https://urgent.news/2026/08/14/tech-stock-hits-52-week-high-at-72-39-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T19:26:28.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/tech-stock-hits-52week-high-at-7239-usd-93CH-4861435"
  },
  "original_language": "en",
  "account": "The tech stock of Bio-Techne Corp has hit a 52-week high, trading at 72.39 USD. This price point marks a 23% gain for the year, with the company's market capitalization standing at $11.27 billion. The stock has seen a 34.94% increase over the past year, though InvestingPro analysis suggests it may be overvalued. The share price rise highlights investor confidence in the company's performance and potential for the future. For a more detailed analysis, readers can refer to the PRO Research Report on TECH, available among 1,400+ US equities on InvestingPro. Stakeholders are currently observing market trends and the company's developments that might affect its status. Recently, Bio-Techne reported its fourth-quarter 2026 results, meeting earnings expectations and exceeding revenue targets with $321.2 million in revenue. This represents a 1% reported growth and a 3% organic increase compared to the same period last year, though a 2% dip was due to the sale of a business unit. The company is also undergoing a potential acquisition by Merck KGaA, Darmstadt, Germany. These factors and performance metrics are vital for investors to consider.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Invesco stock hits 52-week high at 32.56 USD",
        "url": "https://urgent.news/2026/08/14/invesco-stock-hits-52-week-high-at-32-56-usd",
        "published": "2026-08-14T16:20:35.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}